Long-term treatment of essential hypertension with Nadolol and Hydrochlorothiazide: a two-year follow-up.

Abstract

After 3 weeks of placebo administration, thirty-two mildly or moderately hypertensive patients were treated with hydrochlorothiazide (HCZ) for 3 weeks, then with HCZ plus nadolol, a new beta-adrenergic blocker, for 2 years. The dose of HCZ was 50 mg once daily for all except two patients, who received 50 mg twice a day. The dose of nadolol ranged from 40 mg to 240 mg, once daily. The average supine blood pressure decreased from 182/110 mm Hg at the end of the placebo period to 170/104 mm Hg at the end of treatment with HCZ alone. Nadolol was added to the regimen, and the average supine blood pressure decreased further to 132/88 mm Hg at the end of 3 months of combined therapy. It remained essentially unchanged for the duration of the 2-year study, and no increases in the dosage of either drug were needed. Side-effects were mild, and none required a change in dosage. A once-daily dose of nadolol combined with HCZ appears to be safe and effective therapy for the long-term treatment of mild or moderate essential hypertension.

• Authors: M M El-Mehairy, A Shaker, M Ramadan, S Hamza, S S Tadros
• Journal: The Journal of international medical research (J Int Med Res) Vol. 10 Issue 2 Pg. 87-91 ( 1982) ISSN: 0300-0605 [Print] England
• PMID: 6802691 (Publication Type: Clinical Trial, Controlled Clinical Trial, Journal Article)

Chemical References

• Propanolamines
• Hydrochlorothiazide
• Nadolol

Topics

• Drug Therapy, Combination
• Female
• Follow-Up Studies
• Humans
• Hydrochlorothiazide (administration & dosage, adverse effects)
• Hypertension (drug therapy)
• Long-Term Care
• Male
• Middle Aged
• Nadolol
• Propanolamines (administration & dosage, adverse effects)